Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
294.52+2.36 (+0.81%)
At close: 04:00PM EDT
293.70 -0.82 (-0.28%)
After hours: 07:05PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • T
    Thomas
    Securing your investment requires a well-inclined manager that gives the best service, that's why you should invest wisely and Mr Josh Fraser is the best professional trader to start up your investment with.
    Each time I come across this name Mr Josh Fraser I'm always filled with joy. This platform have built a strong trust and relationships with me. That I even make it a point of duty to recommend him to anyone ready and in search for a mentor or broker for invest. I have several achievements from this platform and I'm 100% sure he will still do it for more people, you can contact him on Whats》App +1 (314) 246‑0869 or Tele》gram @Joshfraser1 success... you can contact him on Whats》App +1 (314) 246‑0869 or Tele》gram @Joshfraser1
  • R
    Roku fan
    We are going to 300!
    Bullish
  • C
    Chris
    Great quarter. Most underrated growth stock in the S&P 500. The market is not pricing in the strong pipeline. This is a strong buy here.
    Bullish
  • h
    herb
    Wow, was I wrong about VRTX before earnings!
    I thought big sale of almost $40MM by executive director was not a good sign and bailed out. Also price action was on a downward spiral and it did not look good to me.
    Lost 10 points by doing so but back in at 293 big time and making this the core of my portfolio.
    Great company and I misread the signs.
  • G
    Gene
    So pfizer is looking to buy out a company that has a treatment for sickle cell. How worried is everyone about this? As I understand it Vertex's is in phase II of a gene editing treatment that is showing 100% efficacy. That sounds like a cure to me.

    Any color you guys could shed would be appreciated. I own both companies believe it or not. But I really like Vertex cause they come up with cures not just treatments.
  • J
    JEFFREY P
    Whats next.
    Vertex CEO stated during the Q&A of the 2nd quarter investor conference call last Thursday, that the company will announce in the next few weeks the FDA's decision on the number of patients required for enrollment in the Phase 3 trial using CTX 001 to treat SCD and B thal and the length of time for follow up before allowing submission for NDA and an expected PDUFA date. I suspect given that many of the 75 patients already treated in the phase two trial will have surveillance data extending for several years by the time the phase 3 trial enrollment and treatment is completed in 2023, that just one or two years of follow up for patients treated in the phase 3 trial may be sufficient to confirm that the functional cure provided by CTX001 for these hemoglobinopahties remains durable for both phase 2 and 3 patients without any difference in adverse effects. By my estimates, FDA approval would be possible in 2024. Perhpas ealier in the EU. Hopefully, a more gentle conditioning regimen for the stem cell transplant may available in future clincial trials, allowing even wider application of gene editing to treat milder cases of both SCD and thallasemia and other diseases requiring bone marrow ablative treatment to allow stem cell transplantation.
  • j
    john
    Acadia scraps their ACP-044 pain program. Potential competitor gone.

    Congrats to all the longs on breaking $300 today! :))
    Bullish
  • S
    Sotelo
    They just featured VRTX on this sites morning watchlist. (http://market-engross.club)
  • J
    Jason
    Wouldn’t be surprised if we hit $400 in 2 years.
  • L
    LIVERGOOD
    They just featured VRTX on this sites morning watchlist. (http://market-engross.club)
  • y
    y
    VRTX will likely hit $300 this week. If it can break through $306.10, its 2020, by 19.8, it may have the momentum to touch $330 before Q3 ends.
  • y
    y
    Solid Q2 results. Top and bottom lines beat ValueLine's forecast by 4-5%, quite good considering CF drugs been on the market for years now. Unless something negative is said on the conference call, I anticipate the stock resumes upward trend into $300s. Many promising trials that could bear fruits by 2025. If it doesn't reach my price target soon, I may just hold on to it until 2030. $1000 a share is possible by then if its diabetes and pain trials succeed. The kidney trial is also promising.
  • t
    tobias
    it is sad that vertex gets overlooked.

    4-5% q on q growth this company has preformed every singel quarter for years.
    Bullish
  • P
    Playmakers
    beat and raise, my two favorite words
  • J
    JEFFREY P
    Analysts now need to revise 2023 VRTX revenue and earngings estimates to include the markets opening for VRTX in the treatment of acute pain and possibly neuropathic pain with VX 548, as well as the treatment of appropriate candidates for treatment with sickle cell and beta thal with CTX 001. Add to that the contribution for the new groups of the youngest CF patients allowed to get payment for trikafta
    worldwide. I believe VRTX market cap will be much higher in the next 12 months.
  • j
    john
    Positive AATD results next year could catapult VRTX north of $400. $5 billion potential market in addition to all the other programs. We are a witnessing a superstar being born.
  • T
    Thirdmeinvestor
    There is a special ability that Verve has and no other gene editing companies have yet. It is the ability to deliver gene-editing machinery to the liver cell nucleus. Other companies are working on it, but Verve is using in a clinical trial. I think that Vertex is after this ability.
  • j
    john
    The Viacyte acquisition may have eliminated some potential patent overlap issues down the road as well, although I don't have any direct knowledge of this. All in it appears to have been a brilliant move. If VRTX gets fist mover rights in this space the profits could be mindboggling.
    Bullish
  • T
    Thirdmeinvestor
    https://investors.vrtx.com/news-releases/news-release-details/vertex-advances-vx-548-acute-and-neuropathic-pain
    ]]VX-548 advances into pivotal development for people with acute pain; Phase 3 program to initiate in Q4.[[
  • s
    scott
    Boooooooooooom! I win and whiskers loses AGAIN. Is it $300 yet, BRO? What about #FIVE..is $150 yet? What happened, BRUH?!? You ain’t bro’y enough for this club BRUH! 😂
Advertisement
Advertisement